Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
Xinan Sheng(Peking University), Xinhua Tu(Jiangxi Provincial Cancer Hospital), Zengjun Wang(Nanjing Medical University), Yingchao Zhao(Union Hospital), Xiaobin Yuan(Betta Pharmaceuticals (China)), Qing Zou(Tang Du Hospital), Kehe Chen(The People's Hospital of Guangxi Zhuang Autonomous Region), Guo Jm(Fudan University), Jianming Guo(Sun Yat-sen University), Chaohong He(Shihezi University), Ben Liu(Zhejiang Cancer Hospital), Jun Guo(Hebei Medical University), Zhigang Ji(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Yao(Tianjin Medical University Cancer Institute and Hospital), Lieming Ding(Betta Pharmaceuticals (China)), Xingya Li(Zhengzhou University), Kui Jiang(Dalian Medical University), Cheng Fu(Jiangsu Agri-animal Husbandry Vocational College), Z W Hu(Harbin Medical University), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunpeng Liu(Shenyang Institute of Automation), Dingwei Ye(Fudan University Shanghai Cancer Center), Zhisong He(Peking University), H H Guo(Nanjing Drum Tower Hospital), F J Zhou(Sun Yat-sen University), Q Z Wei(Sichuan University), Yang Wang(Betta Pharmaceuticals (China)), Dahong Zhang(Nanchang University), Ziling Liu(Jilin University), Benkang Shi(Qilu Hospital of Shandong University), Bin Wu(Chinese PLA General Hospital), Gongxian Wang(Nanchang University), Cheng Fu(First Affiliated Hospital of Zhengzhou University), Shukui Qin(Chinese PLA General Hospital), Yunpeng Liu(Nanjing Drum Tower Hospital), Yanqiao Zhang(Harbin Medical University), Peng Chen(Xinjiang Medical University), Hong Luo(Nanjing Agricultural University), Lijie Wang(Chinese PLA General Hospital)
Cited by 20
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis
|Signal Transduction and Targeted Therapy|2020|429